Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Dravet Syndrome · Dravet syndrome · STOK

Stoke Therapeutics

Stoke Therapeutics patent portfolio — 14 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Bedford, USA HQ
2017 Founded
205 Employees
Public company Type
STOK · NYSE Ticker
Company details
Status
Public
HQ
Bedford, USA
Founded
2017
Employees
205
Programs
8
Drugs
4
Patents
14
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Stoke Therapeutics patents

14 pharmaceutical patents indexed for Stoke Therapeutics. 0 expire within 24 months.

Stoke Therapeutics has 14 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

14 patents

Patent portfolio

  1. US 12338437

    OPA1 antisense oligomers for treatment of conditions and diseases

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12060558

    Methods and compositions for treatment of cholesteryl ester storage disease

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11873490

    Antisense oligomers for treatment of conditions and diseases

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11814622

    OPA1 antisense oligomers for treatment of conditions and diseases

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11096956

    Antisense oligomers and uses thereof

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11083745

    Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10913947

    Antisense oligomers for treatment of conditions and diseases

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10683503

    Antisense oligomers for treatment of conditions and diseases

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10188135

    Method for inducing satiety

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10130607

    Methods of reducing blood lactate concentration

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10105344

    Methods of reducing blood lactate concentration

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9198453

    Methods of reducing blood lactate concentration

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9089156

    Reducing muscle soreness with glucosamine compositions

    Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7993690

    Carbohydrate and electrolyte replacement composition

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Stoke Therapeutics have?

14 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Stoke Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.